Character is a precision medicine company that is unlocking the patterns of progressive polygenic diseases, with an initial focus on macular degeneration. Age-related macular degeneration (AMD) impacts one in eight people over the age of fifty and is a leading cause of blindness globally. Our mission is to use human genetics to understand what drives disease progression so we can discover and develop targeted therapies to more effectively treat patients - many of whom lack any treatment options today.
%201.webp)
%202.webp)
Character is a precision medicine company that is unlocking the patterns of progressive polygenic diseases, with an initial focus on macular degeneration. Our mission is to use human genetics to understand what drives disease progression so we can discover and develop targeted therapies to more effectively treat patients - many of whom lack any treatment options today.
In the past, many polygenic diseases have been treated as homogeneous with very little granularity.
The presentation and progression of polygenic diseases are as diverse as the patients they impact. That's why we are building world-class clinical genomic databases in AMD and primary open-angle glaucoma (POAG) to characterize the diversity of patient subtypes and discover the genetic drivers of disease progression.
In the past, many polygenic diseases have been treated as homogenous with very little granularity.
The presentation and progression of polygenic diseases are as diverse as the patients they impact. That’s why we are building world-class clinical genomic databases in AMD and primary open-angle glaucoma (POAG) to characterize the diversity of patient subtypes and discover the genetic drivers of disease progression.
Character is working to increase the probability of success for translating our discoveries into medicines by identifying the right drug targets for the right patients. Character partners with patients, providers, payers, and scientists on observational research studies that integrate genomics with longitudinal clinical data, imaging, and quantitative modeling of disease progression. This platform is the foundation for Character's drug discovery and development pipeline.
Our patient network and integrated data platform power drug discovery and development by enabling prioritization of drug pathways and targets associated with disease progression, clinical trial optimization with patient stratification, and accelerated clinical trial execution.
Hover over left image for more.
Tap the image above for more.
By working with ophthalmologists and other treating physicians, we are determined to understand how diseases behave in real life and tackle the largest unmet needs.
As a patient, you have an opportunity to contribute to research that could deliver better treatments for you and others like you in the future.
As champions of human genetics-based drug discovery and development in ophthalmology, we are harnessing the power of integrated patient data, genomics and machine learning to develop transformative medicines.
